AstraZeneca : Phase III Trial Of Imfinzi Chemoradiotherapy In Lung Cancer Fails To Meet Main Goal

(RTTNews) - The PACIFIC-2 Phase III trial for Imfinzi or durvalumab concurrently administered with chemoradiotherapy did not achieve statistical significance for the primary endpoint of progression-free survival or PFS compared to chemoradiotherapy alone for the treatment of pati https://www.nasdaq.com/articles/astrazeneca-:-phase-iii-trial-of-imfinzi-chemoradiotherapy-in-lung-cancer-fails-to-meet